Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337676632> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2337676632 endingPage "10032" @default.
- W2337676632 startingPage "10032" @default.
- W2337676632 abstract "10032 Background: We recently reported the results in C & A with low risk (group A), intermediate risk (group B) and high risk (group C) mature B-NHL treated on FAB/LMB 96 (Gerrard et al, Br J Haematol, 2008; Patte et al, Blood, 2007; Cairo et al, Blood, 2007, respectively). Adolescent age (15–21 yrs) has historically been considered to be an independent risk factor for poor outcome in subsets of mature B-NHL (Hochberg/Cairo et al, Br J Haematol, 2008; Burkhardt et al, Br J Haematol 2005; Cairo et al, Br J Haematol, 2003). Methods: We analyzed the EFS of all pts treated on FAB/LMB 96 and the following risk factors were significant in a univariate and Cox multivariate analysis: age (<15 vs ≥15 yrs), stage I/II vs III/IV, primary sites, LDH <2 vs ≥2 NL and histology (DLBCL vs BL/BLL). Results: 1111 pts (15%, 15–21 years) were treated with group A (N = 132), group B (N = 744), and group C (N = 235) therapy. Five year EFS (CI95) for all, A, B, C pts was 86% (84%,88%), 98% (93%, 100%), 87%% (84%, 89%), and 79%% (73%,84%), respectively. Age (≥15 yrs), LDH ≥2NL, stage III/IV, and BM+/CNS+ and histology were significant univariate risk factors for decreased EFS (P<0.045, <0.0001, <0.0001, <0.0001, and <0.0001 respectively). Multivariate analysis demonstrated age ≥15 yrs and DLBCL histology were no longer independent significant risk factors (p = .82 and 0.08, respectively), but LDH (RR 2.0, p = .001), stage III/IV (RR 3.8, p<0.001), and primary sites including PMBL (RR 4.0, p<.001) and BM+/CNS+ (RR 2.8, p<0.001) were independent significant risk factors for poorer outcome. Conclusions: With the use of modern short but intense FAB-LMB 96 therapy, adolescent age is no longer a poor risk factor in children with mature B-NHL. The independent risk factors identified in this study (stage, LDH, primary site) for decreased EFS in C & A mature B-NHL will form the basis of the next risk adapted international pediatric mature B-NHL trial. No significant financial relationships to disclose." @default.
- W2337676632 created "2016-06-24" @default.
- W2337676632 creator A5001697191 @default.
- W2337676632 creator A5017985440 @default.
- W2337676632 creator A5041052627 @default.
- W2337676632 creator A5047701227 @default.
- W2337676632 creator A5047962328 @default.
- W2337676632 creator A5064356559 @default.
- W2337676632 creator A5079829314 @default.
- W2337676632 creator A5080068885 @default.
- W2337676632 creator A5081742161 @default.
- W2337676632 creator A5081897500 @default.
- W2337676632 creator A5088448743 @default.
- W2337676632 date "2009-05-20" @default.
- W2337676632 modified "2023-10-14" @default.
- W2337676632 title "Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial" @default.
- W2337676632 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.10032" @default.
- W2337676632 hasPublicationYear "2009" @default.
- W2337676632 type Work @default.
- W2337676632 sameAs 2337676632 @default.
- W2337676632 citedByCount "0" @default.
- W2337676632 crossrefType "journal-article" @default.
- W2337676632 hasAuthorship W2337676632A5001697191 @default.
- W2337676632 hasAuthorship W2337676632A5017985440 @default.
- W2337676632 hasAuthorship W2337676632A5041052627 @default.
- W2337676632 hasAuthorship W2337676632A5047701227 @default.
- W2337676632 hasAuthorship W2337676632A5047962328 @default.
- W2337676632 hasAuthorship W2337676632A5064356559 @default.
- W2337676632 hasAuthorship W2337676632A5079829314 @default.
- W2337676632 hasAuthorship W2337676632A5080068885 @default.
- W2337676632 hasAuthorship W2337676632A5081742161 @default.
- W2337676632 hasAuthorship W2337676632A5081897500 @default.
- W2337676632 hasAuthorship W2337676632A5088448743 @default.
- W2337676632 hasConcept C126322002 @default.
- W2337676632 hasConcept C144301174 @default.
- W2337676632 hasConcept C146357865 @default.
- W2337676632 hasConcept C151730666 @default.
- W2337676632 hasConcept C38180746 @default.
- W2337676632 hasConcept C50440223 @default.
- W2337676632 hasConcept C57742111 @default.
- W2337676632 hasConcept C71924100 @default.
- W2337676632 hasConcept C86803240 @default.
- W2337676632 hasConcept C90924648 @default.
- W2337676632 hasConceptScore W2337676632C126322002 @default.
- W2337676632 hasConceptScore W2337676632C144301174 @default.
- W2337676632 hasConceptScore W2337676632C146357865 @default.
- W2337676632 hasConceptScore W2337676632C151730666 @default.
- W2337676632 hasConceptScore W2337676632C38180746 @default.
- W2337676632 hasConceptScore W2337676632C50440223 @default.
- W2337676632 hasConceptScore W2337676632C57742111 @default.
- W2337676632 hasConceptScore W2337676632C71924100 @default.
- W2337676632 hasConceptScore W2337676632C86803240 @default.
- W2337676632 hasConceptScore W2337676632C90924648 @default.
- W2337676632 hasIssue "15_suppl" @default.
- W2337676632 hasLocation W23376766321 @default.
- W2337676632 hasOpenAccess W2337676632 @default.
- W2337676632 hasPrimaryLocation W23376766321 @default.
- W2337676632 hasRelatedWork W2163263812 @default.
- W2337676632 hasRelatedWork W2339584312 @default.
- W2337676632 hasRelatedWork W2362981704 @default.
- W2337676632 hasRelatedWork W2367054191 @default.
- W2337676632 hasRelatedWork W2367617697 @default.
- W2337676632 hasRelatedWork W2411442805 @default.
- W2337676632 hasRelatedWork W2415741046 @default.
- W2337676632 hasRelatedWork W2740848191 @default.
- W2337676632 hasRelatedWork W3032086589 @default.
- W2337676632 hasRelatedWork W3140385248 @default.
- W2337676632 hasVolume "27" @default.
- W2337676632 isParatext "false" @default.
- W2337676632 isRetracted "false" @default.
- W2337676632 magId "2337676632" @default.
- W2337676632 workType "article" @default.